(2R,3S/2S,3R)-3-(4-Chloro-5-fluoro-6-pyrimidinyl)-2-(2,4-difluorophenyl)butan-2-ol hydrochloride CAS:188416-35-5

(2R,3S/2S,3R)-3-(4-Chloro-5-fluoro-6-pyrimidinyl)-2-(2,4-difluorophenyl)butan-2-ol hydrochloride is employed in medicinal chemistry for its potential pharmacological activities and therapeutic applications. This compound may exhibit anti-proliferative, anti-inflammatory, or enzyme inhibitory properties useful in the treatment of various diseases, including cancer, inflammation, and infectious conditions. In drug discovery, researchers use (2R,3S/2S,3R)-3-(4-Chloro-5-fluoro-6-pyrimidinyl)-2-(2,4-difluorophenyl)butan-2-ol hydrochloride to design and synthesize novel compounds with enhanced potency, selectivity, and bioavailability. By modifying its chemical structure and exploring structure-activity relationships, scientists aim to develop new therapeutic agents targeting specific molecular pathways and biological targets implicated in diseases. Furthermore, this compound serves as a molecular scaffold for the synthesis of potential drug candidates with optimized pharmacokinetic profiles and improved therapeutic efficacy. Its interactions with cellular targets, signaling pathways, and disease biomarkers provide insights into its biological effects and mechanisms of action, guiding the development of targeted therapies and personalized treatments for patients with unmet medical needs. Moreover, (2R,3S/2S,3R)-3-(4-Chloro-5-fluoro-6-pyrimidinyl)-2-(2,4-difluorophenyl)butan-2-ol hydrochloride can be utilized in preclinical studies to evaluate its safety, efficacy, and pharmacological properties before advancing to clinical trials. Its bioactivity, pharmacodynamic effects, and potential side effects are assessed to determine its therapeutic potential and suitability for further development as a pharmaceutical product. Overall, (2R,3S/2S,3R)-3-(4-Chloro-5-fluoro-6-pyrimidinyl)-2-(2,4-difluorophenyl)butan-2-ol hydrochloride represents a valuable compound in medicinal chemistry research, offering opportunities for drug discovery, lead optimization, and therapeutic innovation in the quest to address complex medical conditions and improve patient outcomes.